Abstract:BRD4,as a transcriptional and epigenetic regulator to mediate cellular functions, plays an important role in cancer development.Targeting BRD4 with conventional inhibitors in cancer therapy requires high doses, which often leads to off-target and adverse effects. BRD4-targeted proteolysis-targeting chimeras (PROTACs) can catalytically degrade BRD4 utilizing the endogenous proteasome system, and exhibit promising anti-tumor activity. However, most of the developed PROTACs are non-cancer specific and relatively toxic towards normal cells, limiting their practical applications in cancer treatment. By taking advantage of higher glutathione (GSH) levels in cancer cells than that in normal cells, we developed several GSH-responsive PROTAC precursors 1a-c via the attachment of a GSH-trigger unit on the hydroxyl group of the VHL (von Hippel-Lindau) ligand for the recruitment of E3 ligase. Among the precursors, 1a can be efficiently activated by the innately higher concentrations of GSH in lung cancer cells (A549 and H1299) to release active PROTAC 1, degrading intracellular BRD4 and resulting in cytotoxicity, which is confirmed by mechanistic investigation. On the other hand, 1a cannot be efficiently triggered in normal lung cells (WI38 and HULEC-5a) containing lower levels of GSH, therefore reducing the adverse effects on normal cells. This work provides an alternative proof of concept approach for developing stimuli-responsive PROTAC precursors, and affords a novel insight to improve the selectivity and minimize the adverse effects of current PROTACs, hence enhancing their clinical potential.

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Light-induced Control of Protein Destruction by Opto-Protac.

A PROTAC Augmenter for Photo‐driven Pyroptosis in Breast Cancer

PROTAC Nanoplatform with Targeted Degradation of NAD(P)H:Quinone Oxidoreductase 1 to Enhance Reactive Oxygen Species-Mediated Apoptosis

Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors